News

SEATTLE, WA and VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth quarter and year-end 2023 financial results and provide an update on…

SEATTLE, Wash. and VANCOUVER, British Columbia, March 6, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences. John Bencich, CEO of…

Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025. SEATTLE, Wash. and VANCOUVER, British Columbia, February 29, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that…

$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants.  Upfront net proceeds to provide funds to conduct clinical development of cytisinicline through New Drug Application submission expected in 1H 2025, including the ORCA-OL trial.  Aggregate net proceeds (assuming exercise of all milestone-driven warrants) expected to be sufficient…

SEATTLE and VANCOUVER, British Columbia, December 11, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences. John Bencich, CEO of Achieve,…